title: [Autoimmune disorder secondary to DiGeorge syndrome: a long-term follow-up case report and literature review].
abstract: DiGeorge syndrome is the most common chromosome microdeletion disease. The classical complications include congenital heart disease, hypothyroidism, immunodeficiency, facial abnormalities, and hypocalcemia. According to whether there is an absence or hypoplasia of the thymus, DiGeorge syndrome can be divided into two types, complete DiGeorge syndrome and partial DiGeorge syndrome. The patient was a female born with congenital heart disease, facial abnormalities and cleft palate. When the patient went to school, she had learning difficulty and had problems in communication and personal social behavior. Breath-holding occurred when she was 6 years old. She got infections about 2-3 times a year, which was easy to be cured each time. Chromosome microdeletion test of peripheral blood showed the classical 22q11.2 microdeletion, and no evidence showed that she has thymus absence, thus her disease was diagnosed as partial DiGeorge syndrome. When the patient was 6 years old, the blood routine test showed slight thrombocytopenia, and reexaminations after that indicated the similar result. When 9 years old, she was found with anemia and severe thrombocytopenia. At the age of 10, the patient was admitted to our hospital, complaining of petechia in the body and mucous of mouth. According to the various examinations results, doctors eventually considered the situation as an autoimmune disorder phenomenon. After being treated by pulse-dose methylprednisolone for three days, the bleeding ceased. Then the patient orally took prednisone acetate and pulse-dose cyclophosphamide, however the thrombocyte and hemoglobin levels had not been back to a normal range. But when the dose of prednisone acetate was reduced, the blood platelet count declined again while the hemoglobin kept normal. The long-term follow-up of this case lasted for more than 20 years. Until now, the patient is taking orally prednisone acetate as a maintainance treatment, and the anemia has been improved since, but thrombocytopenia still exists. The mechanism of DiGeorge syndrome in combination with immunodeficiency is still unclear. The most likely reason is that this phenomenon has some relationship with the dysfunction of the thymus and finally had an effect on the function of T cells. The clinical manifestation is always stubborn and need treatment and follow-up visit for a long time.
authors.affiliation: Department of Pediatric, Peking University First Hospital, Beijing 100034, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Xie
authors.affiliation: Department of Pediatric, Peking University First Hospital, Beijing 100034, China.
authors.forename: J Q
authors.initials: JQ
authors.lastname: Guo
authors.affiliation: Department of Pediatric, Peking University First Hospital, Beijing 100034, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Hua
authors.affiliation: Department of Pediatric, Peking University First Hospital, Beijing 100034, China.
authors.forename: W H
authors.initials: WH
authors.lastname: Zhao
authors.affiliation: Department of Pediatric, Peking University First Hospital, Beijing 100034, China.
authors.forename: Q
authors.initials: Q
authors.lastname: Sun
authors.affiliation: Department of Pediatric, Peking University First Hospital, Beijing 100034, China.
authors.forename: X T
authors.initials: XT
authors.lastname: Lu
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology*; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000209:etiology*; D002972:Cleft Palate / Q000209:etiology; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004062:DiGeorge Syndrome / Q000150:complications*; D005145:Face / Q000002:abnormalities; D005260:Female; D005500:Follow-Up Studies; D006330:Heart Defects, Congenital / Q000209:etiology; D006801:Humans; D007859:Learning Disabilities / Q000209:etiology; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D011241:Prednisone / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D000066553:Problem Behavior; D013601:T-Lymphocytes; D013921:Thrombocytopenia / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D003520:Cyclophosphamide; D011241:Prednisone; D008775:Methylprednisolone